BG Medicine to Announce Third Quarter 2012 Earnings Results and Commercial Strategy Update and Host Conference Call on Tuesday, November 13, 2012
WALTHAM, Mass., Nov. 7, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) today announced that the company will host a conference call and webcast on Tuesday, November 13 at 8:00 a.m. Eastern Time to discuss its third quarter 2012 financial results and to provide an update on its commercial strategy. The call and webcast will follow the release of the third quarter financial results before the market opens.
Conference Call Details
To access the live conference call on November 13 at 8:00 a.m. Eastern Time via phone, please dial (877) 845-1016 from the United States and Canada or (708) 290-1155 internationally. Please dial in approximately ten minutes prior to the start of the call.
To access the live and subsequently archived webcast of the conference call, go to the company's Investor Relations section of its website at www.bg-medicine.com . Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
A replay of the call can also be accessed by phone and will be available approximately one hour following the end of the call through November 15, 2012. The replay may be accessed by dialing (855) 859-2056 within the U.S. and Canada or (404) 537-3406 from international locations, conference ID #39743107.
About BG Medicine
BG Medicine, Inc. is a life sciences company focused on the development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3® test for use in patients with heart failure, is available in the United States and Europe. BG Medicine is also developing the CardioSCORETM Test, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com .
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352
CONTACT: Chuck Abdalian EVP & Chief Financial Officer (781) 434-0210
Source: BG Medicine Inc. 2012 GlobeNewswire, Inc.